IP Library Granted Patent US 10,683,285
Granted Patent B2
US 10,683,285 · App. 16/687,474 · Granted Jun 16, 2020

Modulators of hemoglobin

Inventor: Zhe Li (San Diego, CA)
Assignee: Global Blood Therapeutics, Inc.
C07D413/06A61K31/5377A61K31/541C07D417/06
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,683,285
App. No.
16/687,474
Granted
Jun 16, 2020
Kind
B2
Abstract

The present disclosure relates generally to compounds and pharmaceutical compositions suitable as modulators of hemoglobin, and methods for their use in treating disorders mediated by hemoglobin.

Claims (27)

1. A compound of formula:

or a pharmaceutically acceptable salt of each thereof.

2. A compound of formula:

or a pharmaceutically acceptable salt thereof.

3. A compound of formula:

4. A compound of formula:

or a pharmaceutically acceptable salt thereof.

5. A compound of formula:

6. A compound of formula:

or a pharmaceutically acceptable salt thereof.

7. A compound of formula:

8. A compound of formula:

or a pharmaceutically acceptable salt thereof.

9. A compound of formula:

10. A compound of formula:

or a pharmaceutically acceptable salt thereof.

11. A compound of formula:

12. A compound of formula:

or a pharmaceutically acceptable salt thereof.

13. A compound of formula:

14. A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.

15. A pharmaceutical composition comprising a compound of claim 3 and a pharmaceutically acceptable excipient.

16. A pharmaceutical composition comprising a compound of claim 5 and a pharmaceutically acceptable excipient.

17. A pharmaceutical composition comprising a compound of claim 7 and a pharmaceutically acceptable excipient.

18. A pharmaceutical composition comprising a compound of claim 9 and a pharmaceutically acceptable excipient.

19. A pharmaceutical composition comprising a compound of claim 11 and a pharmaceutically acceptable excipient.

20. A pharmaceutical composition comprising a compound of claim 13 and a pharmaceutically acceptable excipient.

Assignments (5)
RELEASE OF SECURITY INTEREST Recorded Oct 6, 2022
From: BIOPHARMA CREDIT PLC, AS COLLATERAL AGENT
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 061620/0186 →
SECOND AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 22, 2021
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 058575/0921 →
AMENDED AND RESTATED PATENT SECURITY AGREEMENT Recorded Dec 9, 2020
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 054664/0871 →
SECURITY INTEREST Recorded Dec 20, 2019
From: GLOBAL BLOOD THERAPEUTICS, INC.
To: BIOPHARMA CREDIT PLC
Reel/Frame 051396/0312 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Dec 9, 2019
From: LI, ZHE
To: GLOBAL BLOOD THERAPEUTICS, INC.
Reel/Frame 051220/0388 →
Continuity (5)
Provisional Application 62883313 · Aug 6, 2019
Provisional Application 62848773 · May 16, 2019
Provisional Application 62821314 · Mar 20, 2019
Provisional Application 62769196 · Nov 19, 2018
Related Publication 20200157085A1 · May 21, 2020
Cited By (2)
US 12,473,277 US 12,649,719